mTOR pathway: A current, up-to-date mini-review (Review)

Oncol Lett. 2014 Dec;8(6):2367-2370. doi: 10.3892/ol.2014.2608. Epub 2014 Oct 10.


Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that was initially identified as the cellular target of rapamycin. This kinase regulates cell growth, proliferation, motility and survival, as well as the gene transcription and protein synthesis that are activated in response to hormones, growth factors and nutrients. Results from preclinical studies have indicated that factors antagonizing the mTOR pathway exert an antitumor effect on lung cancer. Furthermore, primary clinical trials of mTOR inhibitors have demonstrated that the inhibitors may be effective against lung carcinoma. The present study explores the association between mTOR and lung carcinogenesis and describes the clinical trials of mTOR inhibitors.

Keywords: lung cancer; mTOR; targeted therapy.